HOME >> MEDICINE >> NEWS
ARICEPT significantly improves cognition, daily living over Reminyl in Alzheimers patients

GENEVA, SWITZERLAND (4 APRIL 2002) - Results from the first head-to-head study comparing ARICEPT (donepezil HCl tablets) and Reminyl (galantamine HBr tablets) demonstrated significantly greater improvements in cognition and activities of daily living (ADLs) in mild to moderate Alzheimer's disease (AD) patients treated with ARICEPT vs. Reminyl. ARICEPT-treated patients showed significant benefit over patients receiving Reminyl as measured by the modified 13-item Alzheimer's Disease Assessment Scale-cognitive subscale (modified ADAS-cog), achieved significant improvements on the Mini-Mental State Examination (MMSE), and had significantly greater improvements in ADLs, as measured by the Disability Assessment for Dementia (DAD) scale total score. The study was primarily designed to evaluate safety and tolerability. The first-ever presentation of these data took place at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (AAT) in Geneva, Switzerland.

"By comparing two available Alzheimer's disease medications, physicians now have clinical evidence that will help them prescribe the most appropriate treatment for their patients," said study investigator Roy Jones, MD, Research Institute for the Care of the Elderly, St Martin's Hospital, Bath, United Kingdom. "This three month study is encouraging news for mild to moderate Alzheimer's disease patients currently on ARICEPT, as well as those who have yet to initiate treatment." The 12-week, multinational (United Kingdom, Finland, Norway and Germany), head-to-head, randomized open-label study was designed primarily to evaluate the safety and tolerability of ARICEPT (n= 64) and Reminyl (n= 56) in 120 patients with possible or probable mild to moderate Alzheimer's disease. The study also investigated the effects of both treatments on cognition and ADLs, such as meal preparation and finance and correspondence. Trained raters who were blinded to study medication and trial results admin
'"/>


4-Apr-2002


Page: 1 2 3 4

Related medicine news :

1. First-of-its-kind study of vascular dementia patients taking ARICEPT presented at AAGP meeting
2. Vascular dementia patients taking ARICEPT show significant treatment benefits in cognition and function
3. ARICEPT better tolerated than Exelon in patients with mild to moderate Alzheimers disease
4. Moving admitted ER patients into inpatient beds faster could significantly increase hospital revenue
5. Gastrointestinal disorders are associated significantly with sleepless nights
6. Landmark survey reveals asthma in children remains significantly out of control in the United States
7. Data suggest ADDERALL XR significantly improved simulated driving in young adults with ADHD
8. Elderly cancer patients are significantly under-represented in cancer clinical trials
9. Generic anti-inflammatory causes significantly fewer GI complications than branded medications
10. Study shows weight-based REBETOL dosing in combination with PEG-INTRON significantly improves ...
11. Radiotherapy + cetuximab significantly improve disease control and survival in head and neck cancer

Post Your Comments:
(Date:5/26/2015)... Corner, VA (PRWEB) May 26, 2015 ... critical technology and management consulting solutions to the federal ... Technology Strategy and Cloud Solutions. In this newly created ... strategic capabilities and growth in cloud computing, big data, ... join our expanding leadership team as we continue to ...
(Date:5/26/2015)... Norcross, GA (PRWEB) May 26, 2015 ... its line of fresh, all-natural dog foods are now ... Dog Market in Atlanta and The Good Old Dog ... Norcross, Georgia where they’ve recently opened a state-of-the-art, climate ... farmers and farmers’ markets and all of the food ...
(Date:5/26/2015)... New Brunswick (PRWEB) May 26, 2015 ... announce the successful upgrade of the DMi Partners ... This version was the first in Indosoft's contact center ... API improvements, added screen support for such trunk features ... screens, improved lead management, and included upgrades to ...
(Date:5/26/2015)... San Antonio, TX (PRWEB) May 26, 2015 ... announce the opening of its newest clinic on May 25, ... found at 1919 Rogers Road, Suite 102 in Westover Hills ... late as 7 P.M. , “We’re thrilled about opening ... to reach more of our neighbors in San Antonio and ...
(Date:5/26/2015)... 2015 ProTrailer Network is a new ... Pro X . This Effect includes 30 all ... styled text. , ProTrailer Network allows users to ... can easily complement any form of media project. FCPX ... can make professional looking openers. , ProTrailer Network includes ...
Breaking Medicine News(10 mins):Health News:Octo Consulting Group (Octo) Appoints Gaurav “GP” Pal as Vice President of Technology Strategy and Cloud Solutions 2Health News:Allprovide, the All-Natural Pet Food, Available At Georgia Retailers 2Health News:DMi Partners Upgrades to Indosoft Q-Suite 5.8 2Health News:DMi Partners Upgrades to Indosoft Q-Suite 5.8 3Health News:TexPTS Announces New Clinic in San Antonio 2Health News:Developers at Pixel Film Studios Release ProTrailer Network for Final Cut Pro X 2
(Date:5/26/2015)... -- BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical ... XIAFLEX ® in the U.S. and XIAPEX ® ... Tom Wegman , will present a corporate overview ... The presentation will take place on Monday, June ... New York, NY . A live webcast of ...
(Date:5/26/2015)... May 26, 2015 ViiV Healthcare, ... (CHAI) announced today that Aurobindo Pharma has submitted an ... Tentative Approval, to the Food and Drug Administration (FDA), ... ANDA for a generic version of dolutegravir, less than ... sale in the United States . ...
(Date:5/26/2015)... Israel , May 26, 2015 /PRNewswire/ ... Dario™ Diabetes Management Solution, announced today that ... leading HMO, Maccabi Healthcare, it has ... as part of Maccabi,s advanced Telecare unit ... diabetes management solution that enables remote treatment ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. to Present at the Jefferies 2015 Healthcare Conference 2ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 2ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 3ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 4ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 5ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 6ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 7LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 2LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 3LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 4
Cached News: